Pharma giant Novo Nordisk on Wednesday reported booming demand for its weight loss and diabetes drugs Ozempic and Wegovy, but shares sank after the Danish firm disappointed investors with less-than-expected profits for the second quarter and a slimmed-down profit outlook for the year as it facesNovo Nordisk reported net profit of 20.05 billion Danish kroner in the second quarter of 2024, below consensus analyst estimates but an increase of 3% from the same time last year.
The figure marks an increase of a quarter from the same time period last year, when Novo pulled in $7.9 billion in sales. Overall, Novo said the GLP-1 class made up nearly half of sales in the first quarter, around $5.4 billion, up 33% from the same time last year, and the company raised sales expectations for the full year from 19% to 27% at constant exchange rates to 22% to 28%.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: NBCPhiladelphia - 🏆 569. / 51 Read more »
Source: NBCNewYork - 🏆 270. / 63 Read more »
Source: CNBC - 🏆 12. / 72 Read more »
Source: NBCLA - 🏆 319. / 59 Read more »